EGFR変異肺癌でBIM欠失多型性と関係した耐性に対するボリノスタットおよびゲフィチニブを用いた併用治療の第I相試験(VICTROY-J):試験プロトコール

Takeuchi Shinji; Yoshimura Kenichi; Fujiwara Tadami; Ando Masahiko; Shimizu Shinobu; Nagase Katsuhiko; Hasegawa Yoshinori; Takahashi Toshiaki; Katakami Nobuyuki; Inoue Akira; Yano Seiji; Yano Seiji

文献

J-GLOBAL ID：201702238222031828 整理番号：17A1688917

EGFR変異肺癌でBIM欠失多型性と関係した耐性に対するボリノスタットおよびゲフィチニブを用いた併用治療の第I相試験(VICTROY-J):試験プロトコール

Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=17A1688917&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1688917&from=J-GLOBAL&jstjournalNo=U0711A") }}

著者 (12件)： , , , , , , , , , , ,
資料名：
巻： 64 号： 3.4 ページ： 321-325(J-STAGE) 発行年： 2017年
JST資料番号： U0711A ISSN： 1349-6867 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：日本 (JPN) 言語：英語 (EN)

BIM欠失多形性は,ゲフィチニブを含む,EGFR-TKIsで...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1688917&from=J-GLOBAL&jstjournalNo=U0711A") }}

著者キーワード (5件)： , , , ,

腫ようの薬物療法 , 呼吸器の腫よう , 抗腫よう薬の臨床への応用 , 疫学

引用文献 (17件)：

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010
3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012
4. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013
5. Yano S, Takeuchi S, Nakagawa T, Yamada T: Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of HGF and EGFR ligands. Cancer Sci 103: 1189-1194, 2012

, , , , , , , , , , , ,

前のページに戻る